# Oramed Pharmaceuticals Inc.: Form 10-Q for the period ended Mar 31, 2023

- Company: [Oramed Pharmaceuticals Inc.](/companies/ormp.md) (CIK 1176309)
- Form: 10-Q
- Filed: 2023-05-11
- Accepted by EDGAR: May 11, 2023, 17:01 ET
- Period: 2023-03-31
- Accession: 0001213900-23-038593
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1176309/000121390023038593/f10q0323_oramedphar.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1176309/000121390023038593/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $666.0k | us-gaap:Revenues |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $4.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | −$5.2m | us-gaap:OperatingIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 40,041,258 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | −$5.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-01-01 to 2023-03-31 | $199.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | at 2023-03-31 | $155.2m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $159.8m | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $5.0m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2023-03-31 | $151.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 18,494 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the related notes included elsewhere herein and in our consolidated financial statements, accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in our Annual Report.*

### Overview of Operations

We are currently a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins.

We have developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. The excipients in the formulation are not intended to modify the proteins chemically or biologically, and the dosage form is designed to be safe to ingest.

On January 11, 2023, we announced that the ORA-D-013-1 Phase 3 trial did not meet its primary or secondary endpoints. As a result, we terminated this trial and a parallel Phase 3, ORA-D-013-2 clinical trial. We have also initiated a comprehensive analysis of the data of both of these trials, to understand if there is a path forward for our oral insulin candidate. Concurrently, we are examining our existing pipeline and have commenced an evaluation process of potential strategic opportunities, with the goal of enhancing value for our stockholders.

### Oral Insulin

*Type 2 Diabetes*: We conducted the ORA-D-013-1 Phase 3 trial on patients with type 2 diabetes, or T2D, with inadequate glycaemic control who were on two or three oral glucose-lowering agents. The primary endpoint of the trial was to evaluate the efficacy of our oral insulin capsule, ORMD-0801, compared to placebo in improving glycaemic control as assessed by HbA1c, with a secondary efficacy endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks. On January 11, 2023, we announced that the ORA-D-013-1 Phase 3 trial did not meet its primary and secondary endpoints. Following the results of the ORA-D-013-1 Phase 3 trial, we also terminated the ORA-D-013-2 Phase 3 trial, a second Phase 3 trial that included T2D patients with inadequate glycaemic control who were attempting to manage their condition with either diet alone or with diet and metformin.

*NASH*: In December 2020, we initiated a double blind, placebo controlled clinical trial of ORMD-0801 for the treatment of non-alcoholic steatohepatitis, or NASH, in T2D. On September 13, 2022, we reported positive top line results from this trial, demonstrating that ORMD-0801 was safe and well tolerated at 8 mg twice daily dosing, meeting the primary endpoint of no difference in adverse events for ORMD-0801 compared to placebo. The trial also evaluated the effectiveness of ORMD-0801 in reducing liver fat content over the 12-week treatment period by observing several independent measures. All the measurements showed a consistent clinically meaningful trend in favor of ORMD-0801. We are currently evaluating our path forward for ORMD-0801 for NASH.

### Oral Vaccine

On March 18, 2021, we formed Oravax, a 63% owned joint venture to commercialize oral vaccines for COVID-19 and other novel coronaviruses based on Premas Biotech Pvt. Ltd.’s proprietary vaccine technology involving a triple antigen virus like particle. Effective January 1, 2022, Oravax transferred its rights and obligations to its wholly-owned subsidiary, Oravax Medical Ltd. For further details, see note 12 to the audited consolidated financial statements included in our Annual Report.

In December 2021, Oravax commenced a Phase 1 clinical trial, which was divided into two cohorts each comprised of 12 participants. In October 2022, Oravax reported positive preliminary Phase 1 data for Cohort A of this trial, meeting primary and secondary endpoints of safety and immunogenicity. These results included significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in the majority of the patients dosed, and no safety issues were observed, including mild symptoms. Cohort B completed dosing on January 5, 2023 and data is expected in the first half of 2023.

### Results of Operations

### Comparison of three month period ended March 31, 2023 and March 31, 2022

The following table summarizes certain statements of operations data of the Company for the three month periods ended March 31, 2023 and March 31, 2022 (in thousands of dollars except share and per share data):

|  | Three months ended March 31, 2023 | March 31, 2022 |
| --- | ---: | ---: |
| Revenues | $666 | $666 |
| Cost of revenues | - | - |
| Research and development expenses | 4,427 | 5,836 |
| Sales and marketing expenses | 184 | 590 |
| General and administrative expenses | 1,263 | 5,492 |
| Financial income, net | 1,597 | 544 |
| Net loss for the period | $3,611 | $10,708 |
| Basic and diluted loss per share of common stock | $0.08 | $0.27 |
| Weighted average shares of common stock outstanding used in computing basic and diluted loss per share of common stock | 40,041,258 | 38,679,622 |

### Revenues

Revenues consist of proceeds related to the HTIT License Agreement that are recognized on a cumulative basis when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, through the expected product submission date by HTIT of June 2023, using the input method.

Revenues were $666,000 for each of the three month periods ended March 31, 2023 and March 31, 2022.

### Cost of Revenues

Cost of revenues consists of royalties related to the HTIT License Agreement that will be paid over the term of the HTIT License Agreement in accordance with revenue recognition accounting and the Israeli Law for the Encouragement of Industrial Research, Development and Technological Innovation, 1984, as amended, including any regulations or investment tracks promulgated thereunder.

There was no cost of revenues for the three month periods ended March 31, 2023 and March 31, 2022.

### Research and Development Expenses

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, costs of materials, supplies, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses, the full cost of manufacturing drugs for use in research and preclinical development. All costs associated with research and development are expensed as incurred.

Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. We outsource a substantial portion of our clinical trial activities, utilizing external entities such as CROs, independent clinical investigators and other third-party service providers to assist us with the execution of our clinical trials.

Clinical activities, which relate principally to clinical sites and other administrative functions to manage our clinical trials, are performed primarily by CROs. CROs typically perform most of the start-up activities for our trials, including document preparation, site identification, screening and preparation, pre-trial visits, training and program management.

Clinical trial and pre-clinical trial expenses include regulatory and scientific consultants’ compensation and fees, research expenses, purchase of materials, cost of manufacturing of the oral insulin and exenatide capsules, payments for patient recruitment and treatment, as well as salaries and related expenses of research and development staff.

Research and development expenses for the three month period ended March 31, 2023 decreased by 24% to $4,427,000, compared to $5,836,000 for the three month period ended March 31, 2022. The decrease was mainly due to lower expenses related to the Phase 3 trials that were terminated. Stock-based compensation expenses for the three month period ended March 31, 2023 were $17,000, compared to $562,000 during the three month period ended March 31, 2022. This decrease was mainly due to performance equity awards that did not meet their performance conditions during the period ended March 31, 2023.

Following the results of the ORA-D-013-1 Phase 3 trial, which did not meet its primary and secondary endpoints, we terminated both ORA-D-013-1 and ORA-D-013-2 Phase 3 clinical trials. In parallel, we have initiated a comprehensive analysis of the data to understand if there is a path forward for our oral insulin candidate. We are examining our existing pipeline and have commenced an evaluation process of potential strategic opportunities, with the goal of enhancing value for our stockholders.

#### Government grants

In the three month periods ended March 31, 2023 and March 31, 2022, we did not recognize any research and development grants. As of March 31, 2023, we had incurred liabilities to pay royalties to the Israel Innovation Authority of the Israeli Ministry of Economy and Industry of $96,000.

### Sales and Marketing Expenses

Sales and marketing expenses include the salaries and related expenses of our commercial functions, consulting costs and other general costs.

Sales and marketing expenses for the three month period ended March 31, 2023 decreased by 69% to $184,000, compared to $590,000 for the three month period ended March 31, 2022. The decrease was primarily due to lower stock-based compensation expenses and consulting expenses. Stock-based compensation costs for the three month period ended March 31, 2023 were $88,000, compared to $364,000 for the three month period ended March 31, 2022. This decrease was mainly due to performance equity awards that did not meet their performance conditions during the period ended March 31, 2023.

### General and Administrative Expenses

General and administrative expenses include the salaries and related expenses of our management, consulting costs, legal and professional fees, travel expenses, business development costs, insurance expenses and other general costs.

General and administrative expenses for the three month period ended March 31, 2023 decreased by 77% to $1,263,000 compared to $5,492,000 for the three month period ended March 31, 2022. The decrease was mainly due to lower stock-based compensation expenses and legal expenses. Stock-based compensation costs for the three month period ended March 31, 2023 were $67,000, compared to $3,103,000 for the three month period ended March 31, 2022. This decrease was mainly due to equity awards that were granted and vested in the first quarter of 2022 and to performance equity awards that did not meet their performance conditions during the period ended March 31, 2023.

### Financial Income, net

Net financial income increased by 194% to $1,597,000 for the three month period ended March 31, 2023, compared to $544,000 for the three month period ended March 31, 2022. The increase was mainly due to interest from short-term bank deposits.

### Basic and Diluted Loss Per Share of Common Stock

Basic and diluted loss per share of common stock for the three month period ended March 31, 2023 decreased by 70% to $0.08, compared to $0.27 for the three month period ended March 31, 2022. The decrease in loss per share was mainly due to lower net loss resulting from the changes set forth above in the three month period ended March 31, 2023 compared to the three month period ended March 31, 2022.

### Weighted Average Shares of Common Stock Outstanding

Weighted average shares of common stock outstanding for the three month period ended March 31, 2023 were 40,041,258, compared to 38,679,622 for the three month period ended March 31, 2022. The increase was mainly due to shares issued in connection with our controlled equity offering.

### Liquidity and Capital Resources

From inception through March 31, 2023, we have incurred losses in an aggregate amount of $166,476,000. During that period and through March 31, 2023, we have financed our operations through several private placements of our common stock, as well as public offerings of our common stock, raising a total of $255,376,000, net of transaction costs. During that period, we also received cash consideration of $28,001,000 from the exercise of warrants and options. We expect to seek additional financing through similar sources in the future, as needed. As of March 31, 2023, we had $24,104,000 of available cash, $127,363,000 of short-term bank deposits and $2,267,000 of marketable securities.

From inception through March 31, 2023, we have not generated significant revenues from our operations. Management continues to evaluate various financing alternatives for funding new strategic activities, future research and development activities and general and administrative expenses through fundraising in the public or private equity markets. Although there is no assurance that we will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of future third party investments. Based on our current cash resources and commitments, we believe we will be able to maintain our current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that we will not need additional funds prior to such time.

If there are unexpected increases in our operating expenses, we may need to seek additional financing during the next 12 months. Successful completion of our development programs and our transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling our products within the United States, obtaining foreign regulatory approvals to sell our products internationally, or entering into licensing agreements with third parties. There can be no assurance that we will receive regulatory approval of any of our product candidates, and a substantial amount of time may pass before we achieve a level of revenues adequate to support our operations, if at all. We also expect to incur substantial expenditures in connection with the regulatory approval process for each of our product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on our ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. We may also need additional funds to realize the decisions made as part of our strategic review process. We cannot predict the outcome of these activities.

As of March 31, 2023, our total current assets were $155,157,000 and our total current liabilities were $4,972,000. On March 31, 2023, we had a working capital surplus of $150,185,000 and an accumulated loss of $166,476,000. As of December 31, 2022, our total current assets were $157,109,000 and our total current liabilities were $5,746,000. On December 31, 2022, we had a working capital surplus of $151,363,000 and an accumulated loss of $163,081,000. The decrease in working capital from December 31, 2022 to March 31, 2023 was mainly due to a decrease in marketable securities, partially offset by a decrease in accounts payable and accrued expenses.

During the three month period ended March 31, 2023, cash and cash equivalents decreased to $24,104,000, from $40,464,000 as of December 31, 2022. The decrease was mainly due to the reasons described below.

Operating activities used cash of $5,549,000 in the three month period ended March 31, 2023, compared to $9,125,000 used in the three month period ended March 31, 2022. Cash used in operating activities primarily consisted of research and development, sales and marketing and general and administrative expenses and changes in stock-based compensation expenses, interest on deposits, prepaid expenses and account payables and accrued expenses.

Investing activities used cash of $13,203,000 in the three month period ended March 31, 2023, compared to cash provided by investing activities of $7,359,000 in the three month period ended March 31, 2022. Cash used by investing activities in the three month period ended March 31, 2023 consisted primarily of the purchase of short-term deposits partially offset by proceeds from held to maturity securities. Cash provided by investing activities in the three month period ended March 31, 2022 consisted primarily of the proceeds of short-term deposits and held to maturity securities.

Financing activities provided cash of $2,430,000 in the three month period ended March 31, 2023, compared to $2,292,000 provided in the three month period ended March 31, 2022. Cash provided by financing activities consisted primarily of proceeds from the issuance of our common stock.

On September 1, 2021, we entered into a controlled equity offering agreement, or the Cantor Equity Distribution Agreement, with Cantor Fitzgerald & Co., as agent, pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100,000,000, through a sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to our effective shelf registration statement on Form S-3 including a prospectus dated July 26, 2021 and prospectus supplement dated September 1, 2021. We paid the sales agent a cash commission of 3.0% of the gross proceeds of the sale of any shares sold through the sales agent under the Cantor Equity Sales Agreement. As of March 31, 2023, 1,971,447 shares were issued under the Cantor Equity Distribution Agreement for aggregate net proceeds of $26,253,000.

### Critical accounting policies and estimates

Our critical accounting policies are described in “*Management’s Discussion and Analysis of Financial Condition and Results of Operations”* contained in our Annual Report.

### Planned Expenditures

We invest heavily in research and development, and we expect that in the upcoming years our research and development expenses will continue to be our major operating expense.

Following the results of the Phase 3 trials for our oral insulin capsule candidate, ORMD-0801 and the current strategic review initiated by the Company, our obligations may change significantly.

## Market risk

As filed, 278 characters.

There has been no significant change in our exposure to market risk during the quarter ended March 31, 2023. For a discussion of our exposure to market risk, refer to Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” contained in our Annual Report.

## Controls and procedures

As filed, 672 characters.

### Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 11, 2023.
Source: SEC EDGAR, the filing index for accession 0001213900-23-038593. Last ingested by Listed: Nov 15, 2026, 04:14 ET. No prices; not investment advice.
